Patient-derived xenograft models for oncology drug discovery

Abstract

The success of targeted therapies for cancer patients rests on three major components: the right target(s), the right drug and drug combination, and the right patient population. Although much progress has been made in understanding the mechanism of disease and in refi ning pharmaceutical properties of therapeutic agents, the attrition rates between target discovery and drug marketing approval have been high, especially in oncology. One of the main reasons underlying this undesirable statistics is believed to be the lack of predictive power of the model systems used in the preclinical setting. Several strategies have been employed with the aim of improving the predictive value of the preclinical studies, such as incorporating genomic profi ling and molecular segmentation into model selection, and enhancing the development and application of patient-derived xenograft models even during early stage of drug discovery. This brief review will summarize some of the recent concept and practice in incorporating patient-derived models into all stages of drug discovery process, from target to clinical development.

Keywords

Animal models / drug discovery / oncology / patient-derived xenograft / translational research

References

[1] DiMasi JA,Feldman L.Clinical approval success rates for investigational cancer drugs..Clin Pharmacol Ther2013;94:329-35

[2] Kola I.Can the pharmaceutical industry reduce attrition rates?.Nat Rev Drug Discov2004;3:711-5

[3] Rosfjord E,Li G.Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology..Biochem Pharmacol2014;91:135-43

[4] Hanahan D.Hallmarks of cancer: The next generation..Cell2011;144:646-74

[5] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[6] Hoelder S,Workman P.Discovery of small molecule cancer drugs: Successes, challenges and opportunities..Mol Oncol2012;6:155-76 PMCID:PMC3476506

[7] Gibbs JB.Mechanism-based target identification and drug discovery in cancer research..Science2000;287:1969-73

[8] Carter P,Ryan M.Identification and validation of cell surface antigens for antibody targeting in oncology..Endocr Relat Cancer2004;11:659-87

[9] Wang IM,Nickle D,Puig O.Systems biology approach for new target and biomarker identification..Curr Top Microbiol Immunol2013;363:169-99

[10] Rius M.Epigenetic cancer therapy: Rationales, targets and drugs..Oncogene2012;31:4257-65

[11] Jerby L.Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling..Clin Cancer Res2012;18:5572-84

[12] Boven E,Berger DP,Braakhuis BJ,Langdon S.Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study..Cancer Res1992;52:5940-7

[13] Voskoglou-Nomikos T,Seymour L.Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models..Clin Cancer Res2003;9:4227-39

[14] Tentler JJ,Weekes CD,Leong S,Arcaroli JJ,Eckhardt SG.Patient-derived tumour xenografts as models for oncology drug development..Nat Rev Clin Oncol2012;9:338-50 PMCID:PMC3928688

[15] Greenman C,Smith R,Hunter C,Davies H,Butler A,Edkins S,Vastrik I,Avis T,Bhamra G,Choudhury B,Cole J,Forbes S,Halliday K,Hills K,Jenkinson A,Menzies A,Perry J,Richardson D,Small A,Varian J,West S,Yates A,Louis DN,Nicholson AG,Looijenga L,Chiew YE,Greaves MF,Campbell P,Easton DF,Tan MH,Teh BT,Leung SY,Futreal PA.Patterns of somatic mutation in human cancer genomes..Nature2007;446:153-8 PMCID:PMC2712719

[16] Stratton MR,Futreal PA.The cancer genome..Nature2009;458:719-24 PMCID:PMC2821689

[17] Chin L,Futreal PA.Cancer genomics: From discovery science to personalized medicine..Nat Med2011;17:297-303

[18] Berman DM,Orwant RL,Draetta GF,Loda M.Investigative pathology: Leading the post-genomic revolution..Lab Invest2012;92:4-8

[19] Rubio-Viqueira B,Cusatis G,Iacobuzio-Donahue C,Shi C,Danenberg PV,Tanaka K,Salimi-Moosavi H,Amador ML,Kulesza P,Messersmith W,Hruban RH,Hidalgo M.An in vivo platform for translational drug development in pancreatic cancer..Clin Cancer Res2006;12:4652-61

[20] Julien S,Lacroix L,Goéré D,Landron S,Nemati F,Weiswald LB,Morgand L,Gonin P,Job B,Bruno A,De The H,Nunes M,Calvet L,Prevost G,Roman-Roman S,Berthet C.Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer..Clin Cancer Res2012;18:5314-28

[21] Bertotti A,Galimi F,Torti D,Cora D,Buscarino M,Ribero D,Muratore A,Pisacane A,Valtorta E,Risio M,Gambacorta M,Medico E,Marsoni S,Bardelli A.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer..Cancer Discov2011;1:508-23

[22] Petrillo LA,Kapoun AM,Barczak A,Korkaya H,Lewicki J,Park JW,Gray JW,Esserman LJ.Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors..Breast Cancer Res Treat2012;135:913-22 PMCID:PMC3873871

[23] Reyal F,Decraene C,Auger N,De Plater L,Poupon MF,de Cremoux P,Vincent-Salomon A,Roman-Roman S,Decaudin D.Molecular profiling of patient-derived breast cancer xenografts..Breast Cancer Res2012;14:R11

[24] Siolas D.Patient-derived tumor xenografts: Transforming clinical samples into mouse models..Cancer Res2013;73:5315-9 PMCID:PMC3766500

[25] Mardis ER.Genome sequencing and cancer..Curr Opin Genet Dev2012;22:245-50 PMCID:PMC3890425

[26] Baron JA.Screening for cancer with molecular markers: Progress comes with potential problems..Nat Rev Cancer2012;12:368-71 PMCID:PMC3843943

[27] Sleijfer S,Siu LL.Designing transformative clinical trials in the cancer genome era..J Clin Oncol2013;31:1834-41

[28] Golub TR,Tamayo P,Gaasenbeek M,Coller H,Downing JR,Bloomfield CD.Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring..Science1999;286:531-7

[29] Bhattacharjee A,Staunton J,Monti S,Ladd C,Bueno R,Loda M,Mark EJ,Wong W,Golub TR,Meyerson M.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses..Proc Natl Acad Sci U S A2001;98:13790-5 PMCID:PMC61120

[30] Perou CM,Eisen MB,Jeffrey SS,Pollack JR,Johnsen H,Fluge O,Williams C,Lonning PE,Brown PO.Molecular portraits of human breast tumours..Nature2000;406:747-52

[31] Parker JS,Cheang MC,Voduc D,Davies S,He X,Quackenbush JF,Palazzo J,Nobel AB,Nielsen TO,Perou CM.Supervised risk predictor of breast cancer based on intrinsic subtypes..J Clin Oncol2009;27:1160-7 PMCID:PMC2667820

[32] van de Vijver MJ,van't Veer LJ,Hart AA,Schreiber GJ,Roberts C,Parrish M,Witteveen A,Delahaye L,Bartelink H,Rutgers ET,Bernards R.A gene-expression signature as a predictor of survival in breast cancer..N Engl J Med2002;347:1999-2009

[33] Lehmann BD,Chen X,Chakravarthy AB,Pietenpol JA.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies..J Clin Invest2011;121:2750-67 PMCID:PMC3127435

[34] Zhou JX,Deng Q,He P,Zhao M,Chen H,Yin W,He J.Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages..Ann Oncol2013;24:1319-25

[35] Chen Z,Saldivar JS,Bockholt A.EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: One-third of doublets occur at five pairs of amino acids..Oncogene2008;27:4336-43

[36] Peifer M,Sos ML,Seidel D,Plenker D,Sun R,Menon R,Dahmen I,Di Cerbo V,Altmuller J,Becker C,Vandesompele J,Ansen S,Wilkening I,Heuckmann JM,Carter SL,Banerji S,Park KS,Grutter C,Pasqualucci L,Wainer Z,Petersen I,Stoelben E,Schnabel P,Muley T,Engel-Riedel W,Fazio VM,Timens W,Thunnissen E,Heideman DA,Cappuzzo F,Damiani S,Solberg S,Lund-Iversen M,Clement JH,Moch H,Solomon B,Validire P,Brambilla E,Lantuejoul S,Schneider PM,Pao W,Sage J,Schneider R,Wolf J,Perner S,Brindle PK,Thomas RK.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer..Nat Genet2012;44:1104-10 PMCID:PMC4915822

[37] Loukopoulos P,Takamura M,Sakamoto M.Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity..Pancreas2004;29:193-203

[38] DeRose YS,Lin YC,Buys SS,Factor R,Milash BA,Neumayer L,Stijleman IJ,Welm AL.Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes..Nat Med2011;17:1514-20 PMCID:PMC3553601

[39] Zhao X,Yu L,Baxter P,Gurusiddappa S,Su JM,Li XN.Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma..Neuro Oncol2012;14:574-83 PMCID:PMC3337308

[40] McEvoy J,Brennan R,Pounds S,Dyer MA.Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma..PLoS One2012;7:e42739

[41] Morton CL.Establishment of human tumor xenografts in immunodeficient mice..Nat Protoc2007;2:247-50

[42] Goda K,Szabó G.Multidrug resistance through the spectacle of P-glycoprotein..Curr Cancer Drug Targets2009;9:281-97

[43] Reya T,Clarke MF.Stem cells, cancer, and cancer stem cells..Nature2001;414:105-11

[44] Diehn M,Lobo NA,Dorie MJ,Qian D,Ailles LE,Joshua B,Wapnir I,Somlo G,Paz B,Lau SK,Brown JM,Clarke MF.Association of reactive oxygen species levels and radioresistance in cancer stem cells..Nature2009;458:780-3 PMCID:PMC2778612

[45] Zhou J.Cancer stem cells: Models, mechanisms and implications for improved treatment..Cell Cycle2008;7:1360-70

[46] Morrison R,Sun Y,Kim S,Chung CH.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis..J Oncol2011;2011:941876 PMCID:PMC2958340

[47] Hammerman PS,Johnson BE.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer..Clin Cancer Res2009;15:7502-509

[48] Lee JC,Lee KY.Treatment of non-small cell lung carcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitor..Cancer Res Treat2013;45:79-85 PMCID:PMC3710966

[49] Ogino A,Hirano S,Ishiai M,Takigawa N,Kiura K.Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line..Cancer Res2007;67:7807-14

[50] Sadiq AA.MET as a possible target for non-small-cell lung cancer..J Clin Oncol2013;31:1089-96 PMCID:PMC3589702

[51] Zhang Z,Lin L,Au V,Abdel-Rahman M,Levine AD,Choi YJ,Kim SW,Park YS,Lee DH,Miller VA,Ladanyi M,Sawyers C,Ma PC,Taron M,Halmos B.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer..Nat Genet2012;44:852-60

[52] Nurwidya F,Murakami A.Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer..Cancer Res Treat2012;44:151-6 PMCID:PMC3467417

[53] Sequist LV,Dias-Santagata D,Turke AB,Bergethon K,Gettinger S,Akhavanfard S,Temel J,Wain JC,Vernovsky K,Lanuti M,Mino-Kenudson M.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors..Sci Transl Med2011;3:75ra26

[54] Meads MB,Dalton WS.Environment-mediated drug resistance: A major contributor to minimal residual disease..Nat Rev Cancer2009;9:665-74

[55] Huang D,Zhou M,Petillo D,Kahnoski R,Furge KA.Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma..Cancer Res2010;70:1063-71 PMCID:PMC3719378

[56] Shojaei F,Simmons BH,Esparza CO,Feng J,Hu-Lowe DD.HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors..Cancer Res2010;70:10090-100

[57] Shaked Y,Roodhart JM,Langenberg MH,Daenen LG,Xu P,Tang T,Witte L,Bertolini F,Benezra R.Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents..Cancer Cell2008;14:263-73 PMCID:PMC2565587

[58] Bergers G.Modes of resistance to anti-angiogenic therapy..Nat Rev Cancer2008;8:592-603 PMCID:PMC2874834

[59] Olive KP,Davidson CJ,McIntyre D,Madhu B,Caldwell ME,Frese KK,Feig C,Winter SP,Reichelt S,Chang A,Wang L,Grutzmann R,Izeradjene K,Huang P,Plunkett W,Hruban RH,McGovern K,Iacobuzio-Donahue C,Tuveson DA.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer..Science2009;324:1457-61 PMCID:PMC2998180

[60] Krumbach R,Hofmann M,Fiebig HH.Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance..Eur J Cancer2011;47:1231-43

[61] Diaz LAJr,Wu J,Hecht JR,Allen B,Reiter JG,Kinzler KW,Vogelstein B.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers..Nature2012;486:537-40 PMCID:PMC3436069

[62] Shah SP,Goya R,Ha G,Turashvili G,Tse K,Bashashati A,Khattra J,Yap D,McPherson A,Crisan A,Heravi-Moussavi A,Lai D,Varhol R,Dhalla N,Ma K,Griffith M,Cheng SW,Watson P,Chia S,Curtis C,Pharoah PD,Mackey J,Harkins T,Sigaroudinia M,Tlsty T,Meyer IM,Wasserman WW,Huntsman D,Caldas C,Aparicio S.The clonal and mutational evolution spectrum of primary triple-negative breast cancers..Nature2012;486:395-9

[63] Kim MP,Choi W,Chopin-Lally X,Wang H,Hwang R,Abbruzzesse J.Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy..Ann Surg Oncol2012;19 Suppl 3:S395-403

[64] Dong X,English JC,Yee J,Murray N,Ng RT,Lam WL,Ling V,Wang Y.Patient-derived first generation xenografts of non-small cell lung cancers: Promising tools for predicting drug responses for personalized chemotherapy..Clin Cancer Res2010;16:1442-51

[65] Kortmann U,Xue H,Ha G,Shafait S,Cranston AN,Huntsman DG,Gilks CB.Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts..Clin Cancer Res2011;17:783-91

[66] Scott CL,Haluska P.Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment..Front Oncol2013;3:295 PMCID:PMC3849703

[67] Gelmon KA,Mackay H,Robidoux A,Hirte H,Clemons M,Yerushalmi R,Carmichael J.Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study..Lancet Oncol2011;12:852-61

[68] Fiebig HH,Henss H,Löhr GW.Comparison of tumor response in nude mice and in the patients..Behring Inst Mitt1984;74:343-52

[69] Fiebig HH,Hendriks HR.No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone..Anticancer Drugs2000;11:659-64

[70] Mattern J,Hahn EW.Human tumor xenografts as model for drug testing..Cancer Metastasis Rev1988;7:263-84

[71] Némati F,Laurent C,Mariani P,Piperno-Neumann S,Asselain B,Robert D,Donnadieu MH,Bessard MA,Reyes C,Barillot E,Decaudin D.Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors..Clin Cancer Res2010;16:2352-62

[72] Peterson JK.Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development..Eur J Cancer2004;40:837-44

[73] Leggas M,Woo MH,Cheshire PJ,Friedman HS,Houghton PJ.Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts..Clin Cancer Res2002;8:3000-7

[74] Hammer S,Fichtner I,Rolff J,Klar U.Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer..Clin Cancer Res2010;16:1452-65

[75] Wong H,Alicke B,La H,Theil FP,Friedman LS,Gould SE.Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response..Clin Cancer Res2012;18:3846-55

[76] Malaney P,Davé V.One mouse, one patient paradigm: New avatars of personalized cancer therapy..Cancer Lett2014;344:1-12 PMCID:PMC4092874

[77] Nardella C,Patnaik A,Pandolfi PP.The APL paradigm and the "co-clinical trial" project..Cancer Discov2011;1:108-16 PMCID:PMC3222327

[78] Stebbing J,Schwartz GK,Maki R,Morris R,Shankar A,Harding V,Krell J,Katz A.Patient-derived xenografts for individualized care in advanced sarcoma..Cancer2014;120:2006-15 PMCID:PMC4298787

[79] Morelli MP,Ordo-ez E,Viqueira BR,Bruckheimer E,Sidransky D.Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft..J Clin Oncol2012;30:e45-8

[80] Weroha SJ,Enderica-Gonzalez S,Oberg AL,Perkins SE,Butler KA,Fink S,Hou X,Goodman KM,Karlan BY,Kaufmann SH,Haluska P.Tumorgrafts as in vivo surrogates for women with ovarian cancer..Clin Cancer Res2014;20:1288-97 PMCID:PMC3947430

[81] Hidalgo M,Rajeshkumar NV,De Oliveira E,Strawn S,Martell J.A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer..Mol Cancer Ther2011;10:1311-6 PMCID:PMC4629061

[82] Bankert RB,Hess SD.Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies..Trends Immunol2001;22:386-93

[83] Hylander BL,Tang H,Vaughan M,Pitoniak R.Origin of the vasculature supporting growth of primary patient tumor xenografts..J Transl Med2013;11:110 PMCID:PMC3660244

[84] Klemm F.Microenvironmental regulation of therapeutic response in cancer..Trends Cell Biol 2014

[85] Pickup MW,Weaver VM.The extracellular matrix modulates the hallmarks of cancer..EMBO Rep2014;15:1243-53 PMCID:PMC4264927

[86] Bankert RB,Odunsi K,Kelleher RJJr,Simpson-Abelson M,Yokota SJ.Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis..PLoS One2011;6:e24420

[87] Rongvaux A,Martinek J,Gearty SV,Saito Y,Halene S,Manz MG.Development and function of human innate immune cells in a humanized mouse model..Nat Biotechnol2014;32:364-72 PMCID:PMC4017589

[88] Ilie M,Blot L,Long-Mira E,Selva E,Venissac N,Vrignaud P.Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps..Cancer Med2015;4:201-11 PMCID:PMC4329004

[89] Hidalgo M,Biankin AV,Byrne AT,Clarke RB,Jonkers J,Roman-Roman S,Trusolino L.Patient-derived xenograft models: An emerging platform for translational cancer research..Cancer Discov2014;4:998-1013

[90] Xin H,Hu G,Ouyang K,Wang M,Zhu Y.Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts..PLoS One2014;9:e85308